Source content
FAA Guide for Aviation Medical Examiners · Version 10/28/2026 · page 682 · page 1 of 2 of this heading
AASI for Atrial Fibrillation
(Updated 03/27/2024)
AME Assisted Special Issuance (AASI) is a process that provides AMEs the ability to re-issue an
airman medical certificate under the provisions of an Authorization for Special Issuance of a Medical
Certificate (Authorization) to an applicant who has a medical condition that is disqualifying under
Title 14 of the Code of Federal Regulations (14 CFR) part 67.
An FAA physician provides the initial certification decision and grants the Authorization in
accordance with 14 CFR § 67.401. The Authorization letter is accompanied by attachments that
specify the information that treating physician(s) must provide for the re-issuance determination. If
this is a first-time application for an AASI for the above disease/condition, and the applicant has all
the requisite medical information necessary for a determination, the AME must defer and submit all
of the documentation to the AMCD or RFS for the initial determination.
AMEs may re-issue an airman medical certificate under the provisions of an Authorization, if the
applicant provides the following:
• An Authorization granted by the FAA;
• A report of a minimum 24-hour cardiac monitor performed within last 90 days. (Cardiac monitor
report must be submitted, even if findings are normal, and should include 1-page computerized
summary and the representative full-scale multi-lead ECG tracings);
• A completed Non-Valvular Atrial Fibrillation (AFib)/A-Flutter Status Summary and a
cardiologist evaluation that addresses all items on the status report; and
• The above data verifies:
o If all items on the Non-Valvular Atrial Fibrillation (AFib)/A-Flutter
Status Summary are in the left-hand column OR reports verify:
No interval evidence or suspicion of stroke, TIA, or other thromboembolic
event.
Heart rate is well controlled on cardiac monitor by cardiologist
interpretation.
If symptom, rate, or rhythm control is indicated and, if so, a description of
how it this is managed.
When CHA2DS2-VASc score ≥ 2, verify emboli mitigation is in place
without side effects. See Pharmaceuticals – Anticoagulants - Emboli
Mitigation.
The AME must defer to the AMCD or Region if:
• Applicant had left atrial appendage (LAA) occlusion (Watchman)/excision or developed a new
cardiac condition;
• There has been an interval definitive or suspicious thromboembolic event;
• Cardiology interpretation indicates questionable or poor rate control. Average heart rate is
> 100, maximum (non-exercise) is >120, or a single pause is > 3 seconds;
• Evidence that symptoms, rate, or rhythms are not well controlled;
• CHA2DS2-VASc is ≥ 2 and emboli not mitigated; (Acceptable emboli mitigation under AASI
authorization is anti-coagulation with either NOAC/DOAC/warfarin. When using
warfarin/Jantoven, if more than 20% of INR values are less than 2.0 or greater than 3.); and/or
• Interval bleeding that required medical intervention.
FAA Guide for Aviation Medical Examiners, Version 10/28/2026. AME Copilot is an independent reference tool, not affiliated with or endorsed by the FAA. The FAA AME Guide is the authoritative source. Types such as “Special issuance” are reading aids; AME Copilot does not make certification decisions.